VJVirginio Climaco de Araujo Fernandes Junior

Virginio Climaco de Araujo Fernandes Junior

*This is an algorithmically generated author record based on publicly available information.

Virginio Climaco de Araujo Fernandes Junior has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Acquired severe aplastic anemia

    by Luiz Guilherme Darrigo Junior, Gisele Loth, Virginio Climaco de Araujo Fernandes Junior, Alexandre de Albuquerque Antunes, Gabriela Gaspar Filgueiras Landi, Carmem Bonfim

    Acquired severe aplastic anemia is a rare, life-threatening condition characterized by pancytopenia and hypocellularity of the bone marrow. It shows a bimodal age distribution, with approximately 70–80% of cases classified as idiopathic. Recent advances in hematopoietic cell transplantation, immunosuppressive therapy, biological agents, and supportive care have greatly improved survival rates, reaching a 95% cure rate. Differential diagnoses include refractory cytopenia of childhood, inherited bone marrow failure syndromes, and other blood disorders. The aim of this article was to update the Brazilian consensus previously published by the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation in 2021, highlighting the latest developments in the treatment and monitoring of severe aplastic anemia patients undergoing hematopoietic cell transplantation.

  • Open Access

    Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia

    by Ana Luiza de Melo Rodrigues, Adriana Seber, Luciana Domingues, Victor Gottardello Zecchin, Maria Lúcia de Martino Lee, Liane Daudt, Luiza de Souza, Adriana Martins de Sousa, Antonella Adriana Zanette, Carla Nolasco, et al.

    Acute myeloid leukemia (AML) accounts for 15% to 20% of pediatric acute leukemia cases. Treatment failure is influenced by both genetic risk and response to therapy1,2,3,4. Although the initial remission rate exceeds 90%, more than 30-40% of children with AML die of refractory/relapsed disease or treatment-related toxicity5. Improved survival outcomes are associated with comprehensive strategies that combine intensive chemotherapy, effective supportive care, and hematopoietic stem cell transplantation (HCT), adjusted to the relapse risk profile of each patient6-10. In 2020, the Brazilian Group for Pediatric Bone Marrow Transplantation of the Brazilian Society of Bone Marrow Transplantation and Cellular Therapy (SBTMO) and the Brazilian Society for Pediatric Oncology (SOBOPE) convened a task force to provide general guidance on HSCT for childhood AML, to provide evidence-based guidance for the appropriate management of this disease. This is the 2025 update of the previously guideline.

  • Open Access

    Acute graft-versus-host disease

    by Adriana Mello Rodrigues, Rita de Cassia Barbosa da Silva Tavares, Carla Nolasco Monteiro Breviglieri, Marcia de Matos Silva, Roseane Vasconcelos Gouveia, Virgínio Climaco de Araújo Fernandes Junior, Luis Fernando Bouzas

    Despite current advances in graft-versus-host disease (GvHD) prophylaxis, it remains one of the leading causes of morbidity and mortality after hematopoietic cell transplantation (HCT). The first-line therapy for acute GvHD is systemic corticosteroids, but about half of affected patients needs a second-line treatment. Ruxolitinib has been recommended for steroid-refractory GvHD, but treatment costs and adverse events such as cytopenias and infections are limitations. The main second-line alternatives for children are: basilixmab, an anti-interleukin-2-receptor monoclonal antibody, which showed good responses in skin and gut manifestations; extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned before in severe acute GvHD. Novel therapeutical agents are emerging, but their efficacy and safety need further investigation in pediatric patients. We reviewed clinical studies and published recommendations on pediatric acute GvHD that were presented in debate rounds with GvHD experts of the Pediatric Group of the Brazilian Society for Cellular Therapy and Bone Marrow Transplantation. The goal of this consensus is to standardize the prophylaxis, diagnosis, grading, and treatment of acute GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.